arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Protagonist Therapeutics, Inc

PTGX
$135.20 ▼ -8.32 (-5.80%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
47 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Protagonist Therapeutics, Inc faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $8.9B
Dividend Yield —
Revenue Growth 3749.2% ↗
Op. Margin 74.4% ↗
ROIC 18.6% ↗
FCF / Share $3.32 ↗
Trailing P/E 54.7x
Price / Book 10.4x
FCF Yield 2.5%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

47-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$213.47M
↑ +3749.2% —
Net Income Profit after all expenses
$162.85M
↑ +4204.8% —
Operating Margin Operating profit as % of sales
74.4%
↑ +1249.2% 0th
FCF / Share Free cash flow per share
$3.32
↑ +539.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
34
Returns ↑
27
Cash Quality
14

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 13 years · 47 quarters